

**WEDNESDAY 21<sup>st</sup> OCTOBER 2015 COMMENCING 9.30 AM**  
**AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST**  
**LLANEDEYRN, CARDIFF, CF23 9XF**

## **AGENDA**

- |   | <b>Enclosure</b>           |
|---|----------------------------|
| 1. <b>Welcome and introduction</b>  |                            |
| 2. <b>Apologies</b>   |                            |
| 3. <b>Declarations of interest</b>  |                            |
| 4. <b>Minutes of previous meeting</b>   | 1/AWMSG/1015               |
| 5. <b>Chairman's report (verbal update)</b>   |                            |
| 6. <b>Appraisal 1 – Full Submission</b><br><b>Insulin degludec/liraglutide (Xultophy<sup>®</sup>)</b> for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control   | 2/AWMSG/1015<br>Appendices |
| 7. <b>Appraisal 2 - Full Submission</b><br><b>Tiotropium (Spiriva<sup>®</sup> Respimat<sup>®</sup>)</b> indicated as add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta 2 agonists and who experienced one or more severe exacerbations in the previous year | 3/AWMSG/1015<br>Appendices |
| 8. <b>Appraisal 3 - Full Submission</b><br><b>Midodrine hydrochloride (Bramox<sup>®</sup>)</b> in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate   | 4/AWMSG/1015<br>Appendices |
| 9. <b>Appraisal 4 – Limited Submission</b><br><b>Fosfomicin (Fomicyt<sup>®</sup>)</b> for the treatment of the following infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract infections; bacterial meningitis; and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above     | 5/AWMSG/1015<br>Appendices |

10. **Appraisal 5 – Limited Submission**  
**Travoprost (Travatan®)** for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma

6/AWMSG/1015  
Appendices

**Date of next meeting:**  
**Wednesday 11<sup>th</sup> November 2015 in Cardiff**